|
Curatis Holding AG
/ Key word(s): Research Update
MEDIA RELEASE Curatis Holding (SIX:CURN) announces that the life science research company valuationLAB has initiated coverage and has issued an equity research report on the Company which estimates a current risk-adjusted net present value for Curatis Holding of CHF 20.00 per share which corresponds to an enterprise value of CHF 103 million. Liestal, 25 July 2024: Even before its listing on the SIX Swiss Exchange in April 2024, Curatis had a profitable sales portfolio of more than 30 orphan drugs and specialty medicines such as products used to treat life-threatening poisoning. Curatis has built up this portfolio over the past twenty years and has thus achieved a unique position in Switzerland. In addition, Curatis has a pipeline of innovative projects whose development is already at an advanced stage and which can make a significant contribution to Curatis' cash flow from 2025 through upfront and milestone payments as part of partnering agreements. The submission of the application for orphan drug designation in the US and the EU for the most advanced development project (C-PTBE-01) is planned in the second half of 2024, the conclusion of licensing agreements in 2025, and a narrowly defined Phase III trial is scheduled to start in the same year. The launch of the drug is planned for 2027. C-PTBE-01 is intended for use in children suffering from peritumoral brain edema (PTBE) in connection with a diffuse midline glioma brain tumor. According to studies already carried out, C-PTBE-01 leads to significantly fewer side effects than products currently used for treatment. valuationLAB’s equity research report shows a risk-adjusted net present value per share of CHF 20.00. This corresponds to an enterprise value of CHF 103 million, or an increase of 233 per cent compared to the valuation based on the current share price of CHF 6.00. The analyst report of valuationLAB can be downloaded under this link. About the Curatis Group Curatis Holding AG is a listed company (CURN.SW) that specialises in the development and marketing of drugs for rare and very rare diseases. Curatis has a sales portfolio of more than 30 drugs and a pipeline of orphan drug products and specialist products that can make a significant contribution to cash flow from 2025 onwards. You can find more information on the website www.curatis.com. Investor Relations contact: Disclaimer The information contained in this media release and in any link to our website indicated herein is not for use within any country or jurisdiction or by any persons where such use would constitute a violation of law. If this applies to you, you are not authorized to access or use any such information. This media release contains “forward-looking statements” that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “may”, “will”, “should”, “continue”, “believe”, “anticipate”, “expect”, “estimate”, “intend”, “project”, “plan”, “will likely continue”, “will likely result”, or words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside of the control of Curatis Group, that may cause Curatis’ business, strategy or actual results to differ materially from the forward-looking statements (or from past results). For any factors that could cause actual results to differ materially from the forward-looking statements contained in this media release, please see our listing prospectus in connection with the business combination from April 2024. Curatis Group undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance. Persons requiring advice should consult an independent adviser. The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act nor a prospectus under any other applicable laws. Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this media release may vary slightly from the exact arithmetic aggregation of the figures that precede them.
End of Media Release |
| Language: | English |
| Company: | Curatis Holding AG |
| Weierweg 7 | |
| 4410 Liestal | |
| Switzerland | |
| ISIN: | CH1330780979 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1953577 |
| End of News | EQS News Service |
|
|
1953577 25.07.2024 CET/CEST
